Total Payments
$690,395
2024 Payments
$5,229
Companies
17
Transactions
138
Medicare Patients
10,892
Medicare Billing
$14.7M
Payment Breakdown by Category
Other$679,769 (98.5%)
Research$7,123 (1.0%)
Food & Beverage$2,578 (0.4%)
Travel$925.75 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Current or prospective ownership or investment interest | $377,613 | 10 | 54.7% |
| Acquisitions | $302,156 | 1 | 43.8% |
| Unspecified | $7,123 | 17 | 1.0% |
| Food and Beverage | $2,578 | 107 | 0.4% |
| Travel and Lodging | $925.75 | 3 | 0.1% |
Payments by Type
General
$683,272
121 transactions
Research
$7,123
2 transactions
Ownership
$0
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| US Retina LLC | $679,769 | 26 | $0 (2024) |
| F. Hoffmann-La Roche AG | $7,123 | 2 | $0 (2024) |
| Genentech, Inc. | $1,500 | 11 | $0 (2019) |
| Genentech USA, Inc. | $700.12 | 36 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $309.69 | 16 | $0 (2024) |
| Allergan, Inc. | $220.44 | 13 | $0 (2021) |
| ABBVIE INC. | $219.62 | 10 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $100.54 | 7 | $0 (2020) |
| Biogen, Inc. | $86.87 | 4 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $86.50 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,229 | 27 | F. Hoffmann-La Roche AG ($4,645) |
| 2023 | $328.27 | 18 | Genentech USA, Inc. ($174.73) |
| 2022 | $39,376 | 21 | US Retina LLC ($36,564) |
| 2021 | $452,070 | 12 | US Retina LLC ($451,975) |
| 2020 | $82,770 | 6 | US Retina LLC ($82,732) |
| 2019 | $110,034 | 23 | US Retina LLC ($108,497) |
| 2018 | $300.34 | 16 | Genentech, Inc. ($120.23) |
| 2017 | $286.72 | 15 | Regeneron Pharmaceuticals, Inc. ($86.50) |
All Payment Transactions
138 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $21.47 | General |
| Category: Ophthalmology | ||||||
| 11/20/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $19.72 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/19/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $31.16 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/14/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $26.10 | General |
| Category: EYE CARE | ||||||
| 11/12/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $16.86 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/17/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $25.84 | General |
| Category: EYE CARE | ||||||
| 10/16/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $22.42 | General |
| Category: Ophthalmology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $4,644.69 | Research |
| Study: PDS Endophthalmitis Case Series • Category: Ophthalmology | ||||||
| 09/18/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $24.60 | General |
| Category: Immunology and Ophthalmology | ||||||
| 08/28/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $20.52 | General |
| Category: Ophthalmology | ||||||
| 08/08/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $23.45 | General |
| Category: EYE CARE | ||||||
| 08/07/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $20.66 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/01/2024 | Cook Medical LLC | COOK (Device) | Food and Beverage | Cash or cash equivalent | $32.09 | General |
| Category: Urology | ||||||
| 07/24/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $24.60 | General |
| Category: Immunology and Ophthalmology | ||||||
| 07/10/2024 | Biogen, Inc. | BYOOVIZ (Biological) | Food and Beverage | In-kind items and services | $26.54 | General |
| Category: Ophthalmology | ||||||
| 07/09/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $25.19 | General |
| Category: OPHTHALMOLOGY | ||||||
| 06/27/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $27.65 | General |
| Category: EYE CARE | ||||||
| 06/19/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $16.14 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/22/2024 | Sandoz Inc. | Cimerli (Biological) | Food and Beverage | In-kind items and services | $31.98 | General |
| Category: Ophthalmology | ||||||
| 05/01/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $22.76 | General |
| Category: Ophthalmology | ||||||
| 04/23/2024 | Sandoz Inc. | Cimerli (Biological) | Food and Beverage | In-kind items and services | $37.33 | General |
| Category: Ophthalmology | ||||||
| 04/10/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $21.61 | General |
| Category: Immunology and Ophthalmology | ||||||
| 04/03/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $15.57 | General |
| Category: EYE CARE | ||||||
| 02/28/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $26.43 | General |
| Category: Immunology and Ophthalmology | ||||||
| 01/25/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $24.08 | General |
| Category: EYE CARE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PDS Endophthalmitis Case Series | F. Hoffmann-La Roche AG | $4,645 | 1 |
| PDS PHASE 3 ARCHWAY | F. Hoffmann-La Roche AG | $2,478 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 2,431 | 43,328 | $9.9M | $3.2M |
| 2022 | 22 | 2,482 | 16,034 | $9.6M | $3.1M |
| 2021 | 20 | 2,803 | 16,988 | $11.9M | $4.0M |
| 2020 | 20 | 3,176 | 19,228 | $13.3M | $4.5M |
Total Patients
10,892
Total Services
95,578
Medicare Billing
$14.7M
Procedure Codes
83
All Medicare Procedures & Services
83 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 144 | 1,824 | $2.7M | $1.3M | 46.1% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 91 | 32,880 | $2.3M | $955,927 | 41.5% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 138 | 3,098 | $2.5M | $556,168 | 22.4% |
| 67028 | Injection of drug into eye | Office | 2023 | 364 | 1,864 | $1.1M | $164,673 | 15.0% |
| 92134 | Imaging of retina | Office | 2023 | 555 | 2,104 | $336,640 | $58,573 | 17.4% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2023 | 11 | 189 | $56,700 | $30,009 | 52.9% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2023 | 32 | 34 | $141,202 | $29,837 | 21.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 213 | 253 | $129,536 | $22,051 | 17.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 223 | 260 | $94,640 | $15,170 | 16.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 126 | 126 | $85,050 | $14,520 | 17.1% |
| 67228 | Destruction of leaking blood vessels of retina using laser | Office | 2023 | 24 | 47 | $98,700 | $11,838 | 12.0% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 87 | 88 | $43,120 | $8,561 | 19.9% |
| 92250 | Photography of the retina | Office | 2023 | 248 | 328 | $100,040 | $8,357 | 8.4% |
| 67036 | Removal of eye fluid (vitreous) between lens and retina | Facility | 2023 | 11 | 12 | $40,128 | $8,135 | 20.3% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 40 | 40 | $19,920 | $3,701 | 18.6% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 16 | 47 | $35,250 | $2,999 | 8.5% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 28 | 28 | $16,520 | $2,632 | 15.9% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 17 | 43 | $32,250 | $2,387 | 7.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 29 | 29 | $13,195 | $1,900 | 14.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 20 | 20 | $4,540 | $831.49 | 18.3% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 14 | 14 | $3,962 | $472.61 | 11.9% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 228 | 5,594 | $4.5M | $1.2M | 27.9% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 140 | 1,512 | $2.3M | $1.1M | 48.0% |
| J3490 | Unclassified drugs | Office | 2022 | 32 | 169 | $550,200 | $242,181 | 44.0% |
| 67028 | Injection of drug into eye | Office | 2022 | 387 | 1,855 | $1.1M | $167,267 | 15.3% |
About Dr. Harold Brooks, M.D
Dr. Harold Brooks, M.D is a Ophthalmology healthcare provider based in Tallahassee, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1831157890.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Harold Brooks, M.D has received a total of $690,395 in payments from pharmaceutical and medical device companies, with $5,229 received in 2024. These payments were reported across 138 transactions from 17 companies. The most common payment nature is "Current or prospective ownership or investment interest" ($377,613).
As a Medicare-enrolled provider, Brooks has provided services to 10,892 Medicare beneficiaries, totaling 95,578 services with total Medicare billing of $14.7M. Data is available for 4 years (2020–2023), covering 83 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Tallahassee, FL
- Active Since 05/01/2006
- Last Updated 01/20/2015
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1831157890
Products in Payments
- Lucentis (Biological) $7,555
- Non-Covered Product (Drug) $1,351
- OZURDEX (Drug) $440.06
- Vabysmo (Drug) $291.69
- EYLEA AFLIBERCEPT INJECTION (Biological) $189.26
- VABYSMO (Drug) $125.45
- EYLEA HD (Biological) $110.01
- BEOVU (Drug) $89.66
- Cimerli (Biological) $83.41
- EYLEA (Biological) $72.47
- Syfovre (Drug) $67.36
- XIPERE (Drug) $40.04
- COOK (Device) $32.09
- BYOOVIZ (Biological) $26.54
- LIBTAYO (Biological) $24.45
- Izervay (Drug) $22.76
- EVA Ophthalmic Surgical System (Device) $14.37
- DUREZOL (Drug) $10.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Tallahassee
Fang Ko, Md, MD
Ophthalmology — Payments: $36,550
Ophthalmology $36,550
Dr. Charles Newell, M.d, M.D
Ophthalmology — Payments: $29,877
Ophthalmology $29,877
Dr. Robert Steinmetz, M.d, M.D
Ophthalmology — Payments: $29,488
Ophthalmology $29,488
Dr. Emily Ashmore, M.d, M.D
Ophthalmology — Payments: $28,422
Ophthalmology $28,422
Dr. Deanna Louie, M.d, M.D
Ophthalmology — Payments: $24,370
Ophthalmology $24,370
Dr. Tony Weaver, Md, MD
Ophthalmology — Payments: $14,122
Ophthalmology $14,122